Printer Friendly

DANNINGER MEDICAL TECHNOLOGY, INC. REPORTS RECORD FOURTH QUARTER SALES

COLUMBUS, Ohio, March 8 /PRNewswire/ -- Danninger Medical Technology, Inc. (Nasdaq: DANN) today announced record sales for the fourth quarter and the full year 1995.

For the three months ended December 31, 1995, net sales rose 14% to $3,641,000 compared to $3,197,000 for 1994's final quarter. The Company reported net income of $250,000, or $0.05 a share, for the three months ended December 31, 1995, compared to net income of $1,679,000, or $0.04 a share, for the 1994 period.

Net sales for the year ended December 31, 1995, rose to $12,584,000 or a 24% increase over 1994 net sales of $10,154,000. A net loss of $359,000, or $0.08 a share, was reported for the full year compared to net income of $81,000, or $0.02 a share, for 1994.

The sales increase is attributable to demand for the Synergy(TM) Spinal Implant System produced by the Company's Cross Medical subsidiary. Cross received U.S. Food and Drug Administration market clearance in the third quarter of 1995. "We are pleased with the rollout of our new Synergy(TM) Spinal System and the acceptance of the system by spinal surgeons," said Joseph A. Mussey, President and Chief Executive Officer. "The upcoming year has a positive outlook as we continue our rollout of Synergy(TM) and continue to expand and invest in our distribution network." The Company had previously announced receipt of clearance to begin sales of the system in Japan.

Sales were strong for the Company's recovery products. Danninger Medical Technology, Inc. designs, manufactures and markets medical devices that assist patients in their recovery following surgery or trauma. Danninger is a leader in Continuous Passive Motion devices for the knee, hip and hand. Cross Medical Products, Inc., a wholly-owned subsidiary, specializes in developing and marketing spinal implant systems.

FINANCIAL HIGHLIGHTS
 Three Months Ended Three Months Ended
 December 31, 1995 December 31, 1994
 (unaudited) (unaudited)
 Total Revenue $3,641,000 $3,197,000
 Gross Profit 1,907,000 1,464,000


Selling, General and
 Administrative Expenses 1,414,000 884,000
 Research & Development 243,000 240,000
 Income Before Taxes 160,000 292,000
 Net Income 250,000 169,000
 Net Income Per Share $0.05 $0.04


Weighted Average Common

Shares Outstanding including
 Common Stock Equivalents 4,959,998 4,737,362
 Twelve Months Ended Twelve Months Ended
 December 31, 1995 December 31, 1994
 Total Revenue $12,584,000 $10,154,000
 Gross Profit 6,224,000 5,026,000


Selling, General and
 Administrative Expenses 5,215,000 3,394,000
 Research & Development 1,147,000 1,324,000
 (Loss) Income Before Taxes (431,000) 210,000
 Net (Loss) Income (359,000) 81,000
 Net (Loss) Income Per Share ($0.08) $0.02


Weighted Average Shares

Outstanding including Common
 Stock Equivalents 4,661,332 4,695,418
 December 31, 1995 December 31, 1994
 Total Assets $9,517,000 $7,433,000
 Shareholders' Equity 3,522,000 3,390,000
 Working Capital 3,265,000 2,614,000
 -0- 3/8/96


/CONTACT: Paul Miller, Chief Financial Officer, of Danninger Medical Technology, Inc., 614-276-8267/

(DANN)

CO: Danninger Medical Technology, Inc. ST: Ohio IN: MTC SU: ERN

TC-CH -- CLF005 -- 1511 03/08/96 09:41 EST
COPYRIGHT 1996 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 8, 1996
Words:547
Previous Article:SONOCO ANNOUNCES DIVIDEND ON $2.25 SERIES A CUMULATIVE CONVERTIBLE PREFERRED STOCK
Next Article:CRIIMI MAE DECLARES 30 CENTS PER SHARE FIRST QUARTER DIVIDEND; ANNOUNCES MARCH 18 RECORD DATE FOR MAY 7 ANNUAL MEETING
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters